Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricle hypertrophy. The resulting structural and functional abnormalities increase the risk of atrial fibrillation and heart failure. HCM is a notable cause of sudden cardiac death in young Americans, particularly competitive athletes.
Today, we are taking a look at what's recently changed regarding hypertrophic cardiomyopathy in relation to clinical guidance, FDA approvals, and clinical trials.
Current Hypertrophic Cardiomyopathy Guidelines
- British Society of Echocardiography (BSE)
- Published: June 2025
Contemporary Management of the Patients with Hypertrophic Cardiomyopathy
- Canadian Cardiovascular Society (CCS)
- Published: June 2024
Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy
- American College of Cardiology (ACC) / American Heart Association (AHA) / Heart Rhythm Society (HRS) / American Medical Society for Sports Medicine (AMSSM)
- Published: May 2024
Management of Cardiomyopathies
- European Society of Cardiology (ESC)
- Published: August 2023
- (HCM extensively covered in section 7.1)
Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy
- American Society of Echocardiography (ASE)
- Published: May 2022
Recent FDA Approvals for Hypertrophic Cardiomyopathy
Below are the recent medications recently approved by the FDA that we anticipated being incorporated into future clinical guidelines:
Myqorzo (aficamten)
- Cytokinetics
- Approved: December 2025
- For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Camzyos (mavacamten)
- Bristol-Myers Squibb
- Approved: April 2022
- For the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Ongoing Clinical Trials Related to Hypertrophic Cardiomyopathy
The following are ongoing, Phase 3 clinical trials currently recruiting in the United States that we anticipate may impact future hypertrophic cardiomyopathy clinical guidelines.
- A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy (SONATA-HCM)
- Lexicon Pharmaceuticals
- Anticipated Study Completion: August 2026
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). (CEDAR-HCM)
- Cytokinetics
- Anticipated Study Completion: January 2030
Sign up for alerts to keep up with the latest guidelines and insights.
Copyright © 2026 Guideline Central, all rights reserved.